Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer, a study with 5-year follow-up: a plain language summary

Plain Language Summary: What is this summary about? This study investigated a new treatment called nadofaragene firadenovec, also known as Adstiladrin, a gene therapy for patients with non-muscle-invasive bladder cancer that does not respond to the standard BCG treatment. Gene therapy is a type of treatment that uses genetic material to help the body fight or prevent disease. This therapy places a non-replicating virus into the bladder, which carries a gene that helps the body produce a cancer-fighting protein called interferon alfa-2b. The study was designed to assess the safety and effectiveness of this therapy in patients across multiple medical centers in the USA. This study had a 5 year follow-up, meaning the period of time after treatment when doctors continue to check how patients are doing. Researchers collected information about the health of participants for an average of more than 3 years after starting treatment. What were the results? The study found that more than half of the patients treated with Adstiladrin experienced a complete response, meaning no detectable cancer, within three months. About 45% of those who initially responded maintained this response for 12 months. Most side effects were mild or moderate and lasted no more than two days. The most common side effects were bladder spasms and a strong need to urinate. What do the results mean? Researchers concluded that Adstiladrin is a promising new treatment option for non-muscle-invasive bladder cancer patients who do not respond to BCG therapy. It offers a non-surgical option that may help patients avoid bladder removal, with a favorable balance of benefits and risks, making it an important addition to current non-muscle invasive bladder cancer treatment options. This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text.